NeuroDerm Announces Streamlined U.S. Development Plan Following FDA Feedback on ND0612H and ND0612L for the Treatment of Parkinson's Disease
November 11, 2015 07:00 ET
|
NeuroDerm Ltd.
Based on FDA input, NeuroDerm is not required to conduct its largest Phase III pivotal trial of 360 patients
Company to host conference call today at 8:30 a.m. ET
REHOVOT, Israel, Nov. 11, 2015...
NeuroDerm to Host Third Quarter 2015 Financial Results Conference Call on November 11, 2015
November 04, 2015 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Nov. 4, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that...
NeuroDerm Announces 2015 Annual General Meeting of Shareholders
September 24, 2015 08:33 ET
|
NeuroDerm Ltd.
REHOVOT, Isreal, Sept. 24, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm Announces Second Quarter 2015 Financial Results and Provides Corporate Update
August 06, 2015 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Aug. 6, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm to Host Second Quarter 2015 Financial Results Conference Call on August 6, 2015
July 30, 2015 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, July 30, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm Ltd. Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
July 21, 2015 11:44 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, July 21, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the...
NeuroDerm Ltd. Announces Pricing of Public Offering
July 15, 2015 22:01 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, July 15, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the...
NeuroDerm Ltd. Files Registration Statement for Proposed Follow-On Offering
July 02, 2015 17:40 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, July 2, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that...
NeuroDerm Poster Selected for Blue Ribbon Highlights Session During 19th International Congress of Parkinson's Disease and Movement Disorders Annual Meeting
June 18, 2015 15:08 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, June 18, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, announced that its...
NeuroDerm Announces Start of a Pharmacokinetic, Head-To-Head Comparison Study of ND0612H and Duodopa(R)
June 11, 2015 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, June 11, 2015 (GLOBE NEWSWIRE) -- NeuroDerm, Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced...